Why the study?
What is the efficacy of various antiplatelet agents for the primary and secondary prevention of stroke?
What is the efficacy of various antiplatelet agents for the primary and secondary prevention of stroke?
Aspirin remains an effective agent for secondary stroke prevention and an alternative for atrial fibrillation patients contraindicated for warfarin, though its role in primary prevention for low-risk elderly is not supported.
Answers are grounded in this paper and cite their sources.
Supports aspirin in secondary prevention and AF alternatives; leaves open primary prevention utility in low-risk elderly.
Aspirin (acetylsalicylic acid [ASA]) from 75 to 1,300 mg/day is an effective agent in the secondary prevention of stroke. Although no properly designed study has been performed, circumstantial evidence suggests that the favorable effect of ASA for stroke may be enhanced by higher doses. Ticlopidine is more effective than 1,300 mg/day of ASA, and clopidogrel is at least as effective as 325 mg of ASA a day; but, for various reasons, ASA at higher doses is still first choice by many. Three studies have shown no benefit of adding dipyridamole to ASA. A fourth did, but, in addition to other problems, the results are no better than those obtained by higher doses of ASA alone. ASA is an effective alternate to warfarin for patients with atrial fibrillation and contraindications to warfarin. Until a proper study has been performed, ASA is not recommended for the prevention of stroke in a low-risk asymptomatic elderly population.
No takes yet. Share an insight, caveat, or question.
Mark L. Dyken (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: